Objective The MAP-kinase pathway is a major pathway in relaying signals from the plasma membrane into the nucleus. Its comprehensive understanding is needed for rational anti-cancer therapies.SIMAP will develop a comprehensive and robust simulation model of the pathway; populating it with kinetic parameters extracted from the literature and experimental work; simulating various types of inputs into the model; creating qualitative predictions and verifying them with independent experimentations. The model will integrate and analyse data from various types of resources vertically ranging from single molecule information, pathway modelling, up to clinical data and patient's response. SIMAP pioneers the integration of clinical phenotype into this improved biochemical model. Such multi-scale modelling has never been done in the field of Systems Biology and is a step forward.Combining generic mechanistic modelling of the biochemical behaviour, accompanied by new generic mining techniques and clinical data integration, will create a multidisciplinary platform prototype suitable for modelling of other cancer related pathways.Our approach will enable hypothesis-driven research aimed at the establishment of system level computational platforms available for various pharmaceutical applications. The concepts and methods we will develop will lead to the design of new therapeutic drugs, decrease the attrition rate of new drugs and make it possible to select patients on the basis of individual parameters of disease. Modelling-driven predictions regarding the impact of drug combinations will permit us to dramatically improve the design of pre-clinical and clinical trials, enhance patient response and limit adverse effects. Eventually this will optimise Public Health resources leading to significant pharmacoeconomic benefit.The project is lead by a drug and diagnostic discovery SME and an interdisciplinary industrial and academic leading teams of investigators. Fields of science medical and health scienceshealth sciencespublic healthmedical and health sciencesclinical medicineoncology Programme(s) FP6-IST - Information Society Technologies: thematic priority under the specific programme "Integrating and strengthening the European research area" (2002-2006). Topic(s) IST-2004-2.4.11 - Integrated biomedical information for better health Call for proposal Data not available Funding Scheme STREP - Specific Targeted Research Project Coordinator COMPUGEN LTD Address Pinchas rosen street 72 69512 Tel-aviv Israel See on map EU contribution € 0,00 Participants (8) Sort alphabetically Sort by EU Contribution Expand all Collapse all AUREUS PHARMA SA France EU contribution € 0,00 Address Quai de jemmapes 174 75010 Paris 10 See on map CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS Spain EU contribution € 0,00 Address Calle serrano 117 Madrid See on map Links Website Opens in new window FUNDACIO INSTITUT DE RECERCA DE L'HOSPITAL UNIVERSITARI VALL D'HEBRON Spain EU contribution € 0,00 Address Passeig vall d hebron 119-129 08035 Barcelona See on map HALEVI DWECK & CO. ARTTIC ISRAEL COMPANY LTD Israel EU contribution € 0,00 Address 54 haneviim st. Jerusalem See on map Links Website Opens in new window ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI Italy EU contribution € 0,00 Address Via giacomo venezian 1 20133 Milano See on map MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. Germany EU contribution € 0,00 Address Hofgartenstrasse 8 Muenchen See on map Links Website Opens in new window THE UNIVERSITY OF GLASGOW United Kingdom EU contribution € 0,00 Address University avenue G12 8QQ Glasgow See on map THE WEIZMANN INSTITUTE OF SCIENCE Israel EU contribution € 0,00 Address Herzel street 2 76100 Rehovot See on map
